Drawing for CEPAEDEX

USPTO serial 85959272

CEPAEDEX

Reviewed by CopyMark Law Group

Reg. 4673758Status 710
Filing date
Status date
Registration date
Jan 20, 2015
Examiner
REEVES, APRIL ELIZABETH
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.

Status 710: Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active.

Need help with CEPAEDEX?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Michael T. Olsen

Michael T. Olsen Winthrop & Weinstine, P.A.225 South 6th StreetSuite 3500Minneapolis, MN 55402

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical and veterinary preparations and substances for the treatment of epilepsy, convulsions, seizures, pain, multiple sclerosis, neuropathic pain, spinal cord injury, bladder disfunction, peripheral neuropathy, cancer pain, peri-operative pain, rheumatoid arthritis, inflammatory bowel disease, ulcerative colitis, neurogenic symptoms, psychotic disorders, diseases of the central nervous system, stroke and head injury, motion sickness and chemically induced sickness, spasticity, oncology, cancer symptoms, psychiatric illnesses, neurodegenerative diseases, metabolic disorders, obesity, obesity associated with type II diabetes, bulimia, schizophrenia, crohns disease, alzheimers, bone disorders, drug, alcohol and nicotine abuse and inflammatory disorders; pharmaceutical preparations and substances for the treatment of pediatric epilepsy; pharmaceutical and veterinary preparations and substances for the treatment of Dravet syndrome, hypoxic-ischaemic encephalopathy, Lennox-Gastaut syndrome (LGS), intractable childhood epilepsy with generalized tonic-clonic seizures (ICE-GTC), generalized epilepsy with febrile seizures plus (GEFS+), dup 15, and Doose syndrome; herbs for medicinal purposes; medicinal herbs; medicinal oils; medicinal infusions for the treatment of epilepsy, convulsions, seizures, pain, multiple sclerosis, neuropathic pain, spinal cord injury, bladder disfunction, peripheral neuropathy, cancer pain, peri-operative pain, rheumatoid arthritis, inflammatory bowel disease, ulcerative colitis, neurogenic symptoms, psychotic disorders, diseases of the central nervous system, stroke and head injury, motion sickness and chemically induced sickness, spasticity, oncology, cancer symptoms, psychiatric illnesses, neurodegenerative diseases, metabolic disorders, obesity, obesity associated with type II diabetes, bulimia, schizophrenia, crohns disease, alzheimers, bone disorders, hypoxic-ischaemic encephalopathy, drug, alcohol and nicotine abuse and inflammatory disorders; pure extracts of medicinal plants and herbs used for the treatment of epilepsy, convulsions, seizures, pain, multiple sclerosis, neuropathic pain, spinal cord injury, bladder disfunction, peripheral neuropathy, cancer pain, peri-operative pain, rheumatoid arthritis, inflammatory bowel disease, ulcerative colitis, neurogenic symptoms, psychotic disorders, diseases of the central nervous system, stroke and head injury, motion sickness and chemically induced sickness, spasticity, oncology, cancer symptoms, psychiatric illnesses, neurodegenerative diseases, metabolic disorders, obesity, obesity associated with type II diabetes, bulimia, schizophrenia, crohns disease, alzheimers, hypoxic-ischaemic encephalopathy, bone disorders, drug, alcohol and nicotine abuse and inflammatory disorders; herb teas for medicinal purposesSECTION 8 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Sep 15, 2021TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Sep 15, 2021ECDRTEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS—
Sep 15, 2021ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 15, 2021REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Aug 27, 2021C8..CANCELLED SEC. 8 (6-YR)—
Jul 28, 2021ASCKASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY—
Jan 20, 2020REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Jul 25, 2018ASGNAUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP—
Dec 12, 2017CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Dec 12, 2017COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Nov 29, 2017ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Nov 29, 2017REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Jan 20, 2015R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Oct 8, 2014DP1B1(B) BASIS DELETED; PROCEED TO REGISTRATION—
Oct 7, 2014AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Sep 21, 2014IUCNNOTICE OF ALLOWANCE CANCELLED—
Sep 21, 2014D1BRTEAS DELETE 1(B) BASIS RECEIVED—
Jul 8, 2014NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
May 13, 2014NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
May 13, 2014PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Apr 23, 2014NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Apr 10, 2014PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Apr 8, 2014CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Apr 7, 2014TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Apr 7, 2014CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Mar 31, 2014ALIEASSIGNED TO LIE—
Mar 18, 2014TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 18, 2013GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 18, 2013GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 18, 2013CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 15, 2013DOCKASSIGNED TO EXAMINER—
Jun 21, 2013NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jun 17, 2013NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance